{"disease":{"id":"kaposi-s-sarcoma","name":"Kaposi's sarcoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"nab-paclitaxel","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"paclitaxel","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"daunorubicine","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tretinoin","indication_name":"Kaposi's Sarcoma Skin Lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retin-A","generic_name":"TRETINOIN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-beta","drug_class":"Retinoid [EPC]","quality_score":58,"revenue":null,"mechanism":"Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation."},{"drug_id":"hydroxydaunorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vinblastin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vinblastin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"alitretinoin","indication_name":"Kaposi's Sarcoma Skin Lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Panretin","generic_name":"ALITRETINOIN","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Retinoic acid receptor beta","drug_class":"Retinoid [EPC]","quality_score":10,"revenue":null,"mechanism":"Panretin works by binding to retinoic acid receptors in the skin, which helps to slow down the growth of cancer cells."},{"drug_id":"liposomal-doxorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"hydroxydaunomycin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl428647","indication_name":"AIDS-related Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"interferon-alfa-2b","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"daunorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":24,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00339937","title":"Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily","phase":"","overall_status":"COMPLETED","enrollment_count":4622,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00339326","title":"Risk Factors for Non-HIV-Related Kaposi s Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":1383,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00006518","title":"Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1029,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03300830","title":"Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease","phase":"","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06236022","title":"The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05663502","title":"Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":false},{"nct_id":"NCT01352117","title":"Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","has_results":true},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT07066982","title":"Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT05859074","title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT01057121","title":"Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03077451","title":"Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":true},{"nct_id":"NCT00026793","title":"Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions","phase":"","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01495598","title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00001560","title":"Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00006171","title":"Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01016730","title":"Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00055237","title":"Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01752569","title":"A Study of Selumetinib in Patients With Kaposi's Sarcoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Sheffield Teaching Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT02029430","title":"A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":true},{"nct_id":"NCT01276236","title":"Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT00287495","title":"BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04893018","title":"NT-I7 for Kaposi Sarcoma in Patients With or Without HIV","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05846724","title":"Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}